Aug 3 |
et al., Journal of Critical Care, doi:10.1016/j.jcrc.2024.154892 | Antisense therapy to block the Kallikrein-kinin pathway in COVID-19: The ASKCOV randomized controlled trial |
| 151% higher mortality (p=0.08), 81% higher ventilation (p=0.08), and 35% higher progression (p=0.03). RCT 111 hospitalized COVID-19 patients in Brazil showing no clinical benefit with antisense therapy to block the kallikrein-kinin pathway using ISIS 721744 (donidalorsen). Treatment was associated with a significantly higher SOFA score at.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.